Lightspeed Venture Partners

Plus: Abata draws strategic investment from BMS as it preps first human study in multiple sclerosis

Newco uses AI/ML to find bispecific antibodies that can reassemble functional receptor complexes in the face of mutations

Plus: New capital for CytoReason, Truvian and Renalys

Plus: Progentos’ launch; series B rounds for AltruBio, Pheon and Grey Wolf; a series A for Vienna-based Ygion; and more

Xaira will initially aim Baker tech at validated targets; functional genomics and patient data are its plan for “breaking the system” for target discovery

Avalon-incubated biotech now has $161M to advance what could be the first covalent, irreversible protein drugs, starting in oncology

Plus rounds for Rubedo, Flindr, Endeavor, SynOx and more

Plus: Neurosterix launches with a potential competitor to the schizophrenia therapy developed by Karuna

Early 2024 dealmaking activity also included Roche-MOMA, Avenzo-Allorion, AbbVie-Umoja and Boehringer-3T

Plus: Beam moves base editors into the clinic and updates on Star, Tivdak, Olema and Insmed’s Arikayce